192 related articles for article (PubMed ID: 37945147)
1. Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma.
Whitham Z; Hsiehchen D
Surg Oncol Clin N Am; 2024 Jan; 33(1):87-97. PubMed ID: 37945147
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant systemic therapy for hepatocellular carcinoma.
Chick RC; Ruff SM; Pawlik TM
Front Immunol; 2024; 15():1355812. PubMed ID: 38495884
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review.
Tian C; Yu Y; Wang Y; Yang L; Tang Y; Yu C; Feng G; Zheng D; Wang X
Front Immunol; 2024; 15():1352873. PubMed ID: 38440727
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
Marron TU; Fiel MI; Hamon P; Fiaschi N; Kim E; Ward SC; Zhao Z; Kim J; Kennedy P; Gunasekaran G; Tabrizian P; Doroshow D; Legg M; Hammad A; Magen A; Kamphorst AO; Shareef M; Gupta NT; Deering R; Wang W; Wang F; Thanigaimani P; Mani J; Troncoso L; Tabachnikova A; Chang C; Akturk G; Buckup M; Hamel S; Ioannou G; Hennequin C; Jamal H; Brown H; Bonaccorso A; Labow D; Sarpel U; Rosenbloom T; Sung MW; Kou B; Li S; Jankovic V; James N; Hamon SC; Cheung HK; Sims JS; Miller E; Bhardwaj N; Thurston G; Lowy I; Gnjatic S; Taouli B; Schwartz ME; Merad M
Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):219-229. PubMed ID: 35065058
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis.
Ma YN; Jiang X; Song P; Tang W
Biosci Trends; 2024 Mar; 18(1):21-41. PubMed ID: 38382930
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report.
Abdelrahim M; Esmail A; Umoru G; Westhart K; Abudayyeh A; Saharia A; Ghobrial RM
Curr Oncol; 2022 Jun; 29(6):4267-4273. PubMed ID: 35735450
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
8. [Advances in perioperative systemic therapy for hepatocellular carcinoma].
Bai XL; Jia L; Liang TB
Zhonghua Wai Ke Za Zhi; 2020 Oct; 58(10):741-744. PubMed ID: 32993258
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma.
Samuel M; Chow PK; Chan Shih-Yen E; Machin D; Soo KC
Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD001199. PubMed ID: 19160192
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant immunotherapy for resectable hepatocellular carcinoma: a systematic review and meta-analysis.
Han YH; Bo JQ; Liu LX
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):7134-7147. PubMed ID: 37606124
[TBL] [Abstract][Full Text] [Related]
11. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.
Llovet JM; Pinyol R; Yarchoan M; Singal AG; Marron TU; Schwartz M; Pikarsky E; Kudo M; Finn RS
Nat Rev Clin Oncol; 2024 Apr; 21(4):294-311. PubMed ID: 38424197
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis.
Xian F; Wu C; Zhang G; Xu G
Medicine (Baltimore); 2022 Nov; 101(44):e31479. PubMed ID: 36343054
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Yang TK; Yu YF; Tsai CL; Li HJ; Yang PS; Huang KW; Cheng JC
BMC Cancer; 2022 Oct; 22(1):1085. PubMed ID: 36271374
[TBL] [Abstract][Full Text] [Related]
15. Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma.
Zhang B; Yue J; Shi X; Cui K; Li L; Zhang C; Sun P; Zhong J; Li Z; Zhao L
BMJ Open; 2022 Sep; 12(9):e060955. PubMed ID: 36115673
[TBL] [Abstract][Full Text] [Related]
16. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
[TBL] [Abstract][Full Text] [Related]
17. Radiation therapy in the era of immune treatment for hepatocellular carcinoma.
Chen L; Zhang R; Lin Z; Tan Q; Huang Z; Liang B
Front Immunol; 2023; 14():1100079. PubMed ID: 36742293
[TBL] [Abstract][Full Text] [Related]
18. Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift?
Seckler F; Doussot A; Colpart P; Turco C; Calame P; Aubin F; Algros MP; Borg C; Nardin C; Heyd B
J Hepatol; 2020 Dec; 73(6):1588-1590. PubMed ID: 32951909
[No Abstract] [Full Text] [Related]
19. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
[TBL] [Abstract][Full Text] [Related]
20. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
Pinato DJ; Cortellini A; Sukumaran A; Cole T; Pai M; Habib N; Spalding D; Sodergren MH; Martinez M; Dhillon T; Tait P; Thomas R; Ward C; Kocher H; Yip V; Slater S; Sharma R
BMC Cancer; 2021 Mar; 21(1):301. PubMed ID: 33757459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]